Pharma giant AstraZeneca announced plans to acquire FibroGen, Inc.’s China subsidiary for approximately $160 million. Expected to close mid-2025, the deal provides that FibroGen will receive an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback